Physician profile
Jasdeep Miglani
NPI 1326014853
$957,623.85
in general payments reported to CMS, 2019-2025
7 companies · $329K in 2025
The $329K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $110K · 2020: $63K · 2021: $109K · 2022: $77K · 2023: $136K · 2024: $134K · 2025: $329K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $474K · Travel and Lodging: $76K · Consulting Fee: $31K · Food and Beverage: $18K · Education: $259.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $474,113.00 |
| Travel and Lodging | $75,681.07 |
| Consulting Fee | $30,675.00 |
| Food and Beverage | $17,799.58 |
| Education | $258.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $679,038.14 | 2019-2025 | Lybalvi, Aristada, Aristada Initio |
| Teva Pharmaceuticals USA, INC. | $167,353.54 | 2022-2025 | Uzedy |
| E.R. Squibb & Sons, L.L.C. | $110,867.98 | 2024-2025 | Cobenfy |
| Janssen Pharmaceuticals, INC | $180.63 | 2021-2024 | Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $129.98 | 2019 | |
| Travere Therapeutics, INC. | $37.99 | 2024 | |
| Acadia Pharmaceuticals INC | $15.59 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jasdeep Miglani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.